Interferon beta in secondary progressive multiple sclerosis : daily clinical practice

Area of Science:

• Neurology
• Immunology
• Clinical Pharmacology

Background:

• Observational studies offer insights into post-marketing drug behavior.
• Interferon beta-1b (IFNbeta-1b) is used in treating multiple sclerosis.
• Secondary progressive multiple sclerosis (SPMS) is a distinct disease course.

Purpose of the Study:

• To evaluate the effectiveness and safety of IFNbeta-1b in SPMS patients.
• To identify predictors of disability progression in SPMS patients treated with IFNbeta-1b.

Main Methods:

• An independent, open-label, non-randomized observational study.
• 146 SPMS patients treated with IFNbeta-1b between 1998 and 2005 were followed.
• Data collected included demographics, baseline clinical data, and follow-up information.

Main Results:

• Median follow-up was 60 months; 62.2% of patients experienced confirmed progression.
• Patients with >= 2 relapses in the 2 years prior to IFNbeta initiation had a higher risk of disability increase (p=0.002).
• Disease activity (relapses) was the sole predictor of disability increase; 36% discontinued treatment.

Conclusions:

• Higher pre-treatment disease activity in SPMS patients predicts faster disability progression post-IFNbeta initiation.
• IFNbeta-1b was generally safe, with some adverse events noted.
• Pre-treatment relapse rates can help identify SPMS patients needing closer monitoring or alternative therapies.